Yesterday's rights issue announcement aligned closely to the scenario we discussed in our previous r...
On Monday, q.beyond announced and presented its 2028 strategy, including financial targets (2028) an...
Redeye comments on EG7’s announcement of EverQuest Legends, which is a new game based on the origina...
* I väntan på EFSA-beslutet fortsätter etableringen av aXiphen i Brasilien * Den positiva trenden fö...
Cereno Scientific’s FY25 results mark a strategically productive period, with multiple value inflect...
We look for mid-single growth in CDON’s group GMV in Q1.
Mendus has announced a new clinical collaboration with the Olivia Newton-John Cancer Research Instit...
This morning, OXE Marine announced a raise of SEK60m, which includes a directed share issue and conv...
* Produktlanseringar och skalbarhet ger lönsam tillväxt * Starkt 2025 ger medvind framöver * Vi inle...
Redeye comments on Alligator Bioscience’s outcome of its TO14 warrant exercise, which adds approxima...
Q1 2026E is set to show improving profitability in Technology & Distribution, while Energy & Environ...
Redeye has opened an Analyst Q&A following the recent share price movement and unusually high tradin...
* Clear initiatives for efficiency gains presented * Focus on add-on sales and M&A to re-accelerate ...
Efter en omfattande turnaround med stärkta marginaler och pressade returgrader har Nelly Group trans...
Last evening, Insplorion communicated a higher bid for its core business from Consilium, totaling ap...
Redeye provides an update on Biovica following the Q3 2025/2026 report, which overall came in slight...
Redeye comments on Better Collective’s announcement of expansion into prediction markets with the la...
Genovis announces a strategic partnership with Dutch CRO Single Cell Discoveries.
* A directed share issue adds MSEK 4.2 before costs * First patient enrolment expected as next trigg...
Agtira står inför ett skifte mot lönsam tillväxt efter förvärvet av Pepino.